Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10146645 | 0.88 | GRM2 (0.49) | GRM2PARG | |
| SCHEMBL10146651 | 0.84 | GRM2 (0.50) | GRM2PARG | |
| SCHEMBL10145959 | 0.82 | GRM2 (0.72) | GRM2POLBPARG | |
| SCHEMBL10146361 | 0.82 | GRM2 (0.62) | GRM2KDM4EPARGALDH1A1 | |
| SCHEMBL10146655 | 0.82 | GRM2 (0.48) | GRM2PARG | |
| SCHEMBL10146658 | 0.82 | GRM2 (0.50) | GRM2PARG | |
| SCHEMBL627147 | 0.79 | GRM2 (0.46) | GRM2PARGPIK3CD | |
| SCHEMBL10146661 | 0.78 | GRM2 (0.55) | GRM2PARGPIK3CD | |
| SCHEMBL10145944 | 0.78 | GRM2 (0.59) | GRM2PARG | |
| SCHEMBL10145933 | 0.77 | GRM2 (0.58) | GRM2PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |